Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861257 | 0.83 | TSHR (0.70) | FOLH1CA1CA2CA9TSHR | |
| SCHEMBL9851069 | 0.82 | LOXL2 (0.61) | TSHRMRGPRX4 | |
| SCHEMBL6825536 | 0.81 | TSHR (0.67) | CA1CA2CA9TSHRPLA2G2A | |
| SCHEMBL1926951 | 0.81 | FOLH1 (0.66) | FOLH1PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL70351 | 0.80 | FOLH1 (0.70) | FOLH1PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL30791058 | 0.80 | FOLH1 (0.70) | FOLH1PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL12989233 | 0.78 | FOLH1 (0.50) | FOLH1CA1CA2CA9TSHR | |
| SCHEMBL12775045 | 0.78 | FOLH1 (0.58) | FOLH1PRSS1PRSS2PRSS3CA1 | |
| Acetic Acid SCHEMBL28180936 | 0.78 | LMNA (0.48) | TSHRPTPN1PLA2G2A | |
| SCHEMBL26567800 | 0.77 | ALDH1A1 (0.72) | CA1CA2CA9TSHRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113173885-A | Method for synthesizing benzydamine hydrochloride impurity B | 龙曦宁（上海）医药科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-113173885-A | Method for synthesizing benzydamine hydrochloride impurity B | 龙曦宁（上海）医药科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | FOLH1 4501/4885PRSS1 1758/4885PRSS2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.